Translational research in central nervous system drug discovery

被引：60

作者：

Hurko O. ^{[1
,2
]}

Ryan J.L. ^{[1
]}

机构：

[1] Translational Research, Wyeth, Collegeville

[2] Clinical Discovery, Translational Research, Wyeth, Collegeville

来源：

NeuroRX | 2005年 / 2卷 / 4期

关键词：

Biomarkers; CNS; Drug discovery; Imaging; Proteomics; Translational research;

D O I：

10.1602/neurorx.2.4.671

中图分类号：

学科分类号：

摘要：

Of all the therapeutic areas, diseases of the CNS provide the biggest challenges to translational research in this era of increased productivity and novel targets. Risk reduction by translational research incorporates the "learn" phase of the "learn and confirm" paradigm proposed over a decade ago. Like traditional drug discovery in vitro and in laboratory animals, it precedes the traditional phase 1-3 studies of drug development. The focus is on ameliorating the current failure rate in phase 2 and the delays resulting from suboptimal choices in four key areas: initial test subjects, dosing, sensitive and early detection of therapeutic effect, and recognition of differences between animal models and human disease. Implementation of new technologies is the key to success in this emerging endeavor. © The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：671 / 682

页数：11

共 134 条

[1]

Drews J., In Quest of Tomorrow's Medicines, (1998)

[2]

Sheiner L., Learning versus confirming in clinical drug development, Clin Pharm Ther, 61, pp. 275-291, (1997)

[3]

Schadt E.E., Monks S.A., Friend S.H., A new paradigm for drug discovery: Integrating clinical genetic, genomic and molecular phenotype data to identify drug targets, Biochem Soc Trans, 31, pp. 437-443, (2003)

[4]

Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G., Correlative memory deficits, A-β elevation, and amyloid plaques in transgenic mice, Science, 274, pp. 99-103, (1996)

[5]

Citron M., Westaway D., Xia W., Carlson G., Diehl T., Levesque G., Johnson-Wood K., Lee M., Seubert P., Davis A., Kholodenko D., Motter R., Sherrington R., Perry B., Yao H., Strome R., Lieberburg I., Rommens J., Kim S., Schenk D., Fraser P., St. George Hyslop P., Selkoe D.J., Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice, Nat Med, 3, pp. 67-72, (1997)

[6]

Saunders A.M., Strittmatter W.J., Schmechel D., St. George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M., Hulette C., Grain B., Goldgaber D., Roses A.D., Association of apolipoprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease, Neurology, 43, pp. 1467-1472, (1993)

[7]

Harris F.M., Brecht W.J., Xu Q., Tesseur I., Kekonius L., Wyss-Coray T., Fish J.D., Masliah E., Hopkins P.C., Scearce-Levie K., Weisgraber K.H., Mucke L., Mahley R.W., Huang Y., Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice, Proc Nat Acad Sci USA, 100, pp. 10966-10971, (2003)

[8]

Evans R.M., Hui S., Perkins A., Lahiri D.K., Poirier J., Farlow M.R., Cholesterol and APOE genotype interact to influence Alzheimer disease progression, Neurology, 62, pp. 1869-1871, (2004)

[9]

Dufouil C., Richard F., Fievet N., Dartigues J.F., Ritchie K., Tzourio C., Amouyel P., Alperovitch A., APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The Three-City Study, Neurology, 64, pp. 1531-1538, (2005)

[10]

Hurko O., Genetics and genomics in neuropsychopharmacology: The impact on drug discovery and development, Eur Neuropsychopharmacol, 11, pp. 491-499, (2001)

← 1 2 3 4 5 6 7 8 9 10 →